• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Jan. 29, 2020

View Archived Issues
Coronavirus-test-tube.png

Hong Kong researchers develop coronavirus vaccine

HONG KONG – As drug developers are racing to find a cure for the new coronavirus, researchers in Hong Kong claim to have made major headway in the development of a vaccine for the virus that has so far killed 132. Yuen Kwok-yung, the chair of infectious diseases at the University of Hong Kong’s (HKU) department of microbiology, said in a press briefing at Hong Kong’s Queen Mary Hospital that his team had successfully isolated the novel virus from the first imported case in Hong Kong. But he said the vaccine still needs months to be tested on animals and an additional year for human trials before it is fit for use.

Read More
Coronavirus.png

HHS Secretary: No emergency here … yet

Despite pressure from several lawmakers to declare the new coronavirus a U.S. public health emergency, Health and Human Services (HHS) Secretary Alex Azar said such a declaration isn’t needed, at least not yet. Read More
Coronavirus-Wuhan-virus-alert-keyboard.png

NCoV’s spread is rapid, but so are communications, countermeasures

LONDON – It has gone from “pneumonia of unknown cause” affecting 44 patients in Wuhan, China, on Jan. 5, 2020, to spark a global health alert, with the World Health Organization (WHO) now looking likely to declare the outbreak of the novel coronavirus, 2019-nCoV, a public health emergency of international concern (PHEIC) less than four weeks later. Read More

BioWorld tracks the Wuhan coronavirus outbreak

See BioWorld’s ongoing coverage of the 2019-nCoV coronavirus outbreak.

Read More
Brain-organoid-1-1-29.png

Stress, identity crises part of growing up – for organoids

When developmental neurobiologist Arnold Kriegstein talks about his work, it sounds for all the world like he is talking about the brains of teenagers. They are stressed. Their identity is mixed up. But putting them in a good environment is helpful to their development. Kriegstein, though, was describing brain organoids. Read More

Derm drug developer Timber seeks public listing in Biopharmx merger

Timber Pharmaceuticals LLC, a startup created by New Jersey-based investment and operating firm Tardimed Sciences LLC, said it's poised to make a fresh leap into the public market this year with plans to take over Biopharmx Corp.'s NYSE listing in a new reverse merger deal. Read More

Presto, Entresto: Win by Bayer, Merck with vericiguat could set up combo ploy in HF as Cytokinetics advances

Bayer AG and Merck & Co. Inc. took Wall Street by surprise in November with their phase III success testing vericiguat in heart failure (HF), such that the guanylate cyclase stimulator’s odds not only have improved significantly but also in a different way than imagined before. Read More

Cell therapy firm Agex looks west to expand into Japan

In its first step into Japan, Agex Therapeutics Inc. accelerates its development of engineering hypoimmunogenic cells, universal cells that can be used on patients who didn’t generate the original cell and without the need to use immunosuppressants. Read More

Appointments and advancements for Jan. 29, 2020

New hires and promotions in the biopharma industry, including: Aicure, Bavarian Nordic, Century, Decibel, Disc, Passage, Pendulum, Verrica Read More

Financings for Jan. 29, 2020

Biopharmas raising money in public or private financings, including Alector, Annovis, Atyr, Biohaven, Cocrystal, Denali, Idbydna, Salarius, Trillium Read More

In the clinic for Jan. 29, 2020

Clinical updates, including trial initiations, enrollment status and data readouts and publications, including Akcea, Delmar, Emmaus, Exopharm, Geneos, Intercept, Orexo, Satsuma, Unum, Vasopharm, Verastem Read More

Other news to note for Jan. 29, 2020

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief, including Addex, Allergy Therapeutics, Celularity, Chimerix, Conatus, Cytodyn, Cyxone, Decibel, Fibrogenesis, Galmed, Genfit, Gilead, Hepion, Histogen, Hoth, Innovation, Isoprene, Johnson & Johnson, Madrigal, Microcures, Merck, Mogrify, Nymox, Oncology Pharma, Onxeo, Otonomy, Sorrento, Spinalcyte, Spring Bank, Syros, Veloxis, Wuxi Read More

Regulatory actions for Jan. 29, 2020

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations, including Cabaletta, Exelixis, Fulcrum, Galapagos, Janssen, Kite, Lilly, Orchard, Teva Read More

Regulatory front for Jan. 29, 2020

The latest global regulatory news, changes and updates affecting biopharma. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 20, 2025.
  • Brain, syringe hovering over hands

    NICE rejects Lilly‘s Kisunla and Eisai‘s Leqembi

    BioWorld
    To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved Alzheimer’s disease drugs are too small...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe